Research programme: betulinic acid derivatives - Derm-Biome Pharmaceuticals
Latest Information Update: 12 Jan 2023
At a glance
- Originator Novelix Pharmaceuticals
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antineoplastics; Skin disorder therapies; Small molecules
- Mechanism of Action Antioxidants; Cytokine inhibitors; Interleukin 17 inhibitors; Microbiome modulators; NF-E2-related factor 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis; Psoriasis; Squamous cell cancer